http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 26 May 2026 09:41:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Insilico+Medicine+and+Human+Longevity+Announce+Collaboration+to+Co-Develop+Industry-First+AI+Foundation+Model+for+Longevity+Science/26547128.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >Cambridge, Mass.</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, and <span>Human Life Foundation Models, Inc.</span> (HLFM), a newly launched company established by <span value="ACORN:1100353349" idsrc="xmltag.org" >Human Longevity, Inc.</span> today announced a multi-million-dollar AI co-development collaboration to build industry's first large-scale foundation models dedicated to human longevity science.</p> <p>As aging populations reshape global labor markets and consumer demand, longevity has transcended its origins as a niche scientific pursuit to become a major economic pillar. According to recent analysis by <span>UBS</span>, the global longevity market is currently http://www.streetinsider.com/Press+Releases/Insilico+Medicine+and+Human+Longevity+Announce+Collaboration+to+Co-Develop+Industry-First+AI+Foundation+Model+for+Longevity+Science/26547128.html Tue, 26 May 2026 09:41:00 -0400 3696 A.11003533 O.24152401 O15 http://www.streetinsider.com/Press+Releases/Insilico+Medicine+and+Human+Longevity+Announce+Collaboration+to+Co-Develop+Industry-First+AI+Foundation+Model+for+Longevity+Science/26547128.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >Cambridge, Mass.</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, and <span>Human Life Foundation Models, Inc.</span> (HLFM), a newly launched company established by <span value="ACORN:1100353349" idsrc="xmltag.org" >Human Longevity, Inc.</span> today announced a multi-million-dollar AI co-development collaboration to build industry's first large-scale foundation models dedicated to human longevity science.</p> <p>As aging populations reshape global labor markets and consumer demand, longevity has transcended its origins as a niche scientific pursuit to become a major economic pillar. According to recent analysis by <span>UBS</span>, the global longevity market is currently http://www.streetinsider.com/Press+Releases/Insilico+Medicine+and+Human+Longevity+Announce+Collaboration+to+Co-Develop+Industry-First+AI+Foundation+Model+for+Longevity+Science/26547128.html Tue, 26 May 2026 09:41:00 -0400 3696 A.11003533 O.24152401 O15 http://www.streetinsider.com/Press+Releases/Insilico+Medicine+and+Human+Longevity+Announce+Collaboration+to+Co-Develop+Industry-First+AI+Foundation+Model+for+Longevity+Science/26547128.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >Cambridge, Mass.</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, and <span>Human Life Foundation Models, Inc.</span> (HLFM), a newly launched company established by <span value="ACORN:1100353349" idsrc="xmltag.org" >Human Longevity, Inc.</span> today announced a multi-million-dollar AI co-development collaboration to build industry's first large-scale foundation models dedicated to human longevity science.</p> <p>As aging populations reshape global labor markets and consumer demand, longevity has transcended its origins as a niche scientific pursuit to become a major economic pillar. According to recent analysis by <span>UBS</span>, the global longevity market is currently http://www.streetinsider.com/Press+Releases/Insilico+Medicine+and+Human+Longevity+Announce+Collaboration+to+Co-Develop+Industry-First+AI+Foundation+Model+for+Longevity+Science/26547128.html Tue, 26 May 2026 09:41:00 -0400 3696 A.11003533 O.24152401 O15 http://www.streetinsider.com/Press+Releases/Insilico+Medicine+and+Human+Longevity+Announce+Collaboration+to+Co-Develop+Industry-First+AI+Foundation+Model+for+Longevity+Science/26547128.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >Cambridge, Mass.</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, and <span>Human Life Foundation Models, Inc.</span> (HLFM), a newly launched company established by <span value="ACORN:1100353349" idsrc="xmltag.org" >Human Longevity, Inc.</span> today announced a multi-million-dollar AI co-development collaboration to build industry's first large-scale foundation models dedicated to human longevity science.</p> <p>As aging populations reshape global labor markets and consumer demand, longevity has transcended its origins as a niche scientific pursuit to become a major economic pillar. According to recent analysis by <span>UBS</span>, the global longevity market is currently http://www.streetinsider.com/Press+Releases/Insilico+Medicine+and+Human+Longevity+Announce+Collaboration+to+Co-Develop+Industry-First+AI+Foundation+Model+for+Longevity+Science/26547128.html Tue, 26 May 2026 09:41:00 -0400 3696 A.11003533 O.24152401 O15 http://www.streetinsider.com/PRNewswire/Insilico+Medicine+and+Human+Longevity+Announce+Collaboration+to+Co-Develop+Industry-First+AI+Foundation+Model+for+Longevity+Science/26547128.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >Cambridge, Mass.</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, and <span>Human Life Foundation Models, Inc.</span> (HLFM), a newly launched company established by <span value="ACORN:1100353349" idsrc="xmltag.org" >Human Longevity, Inc.</span> today announced a multi-million-dollar AI co-development collaboration to build industry's first large-scale foundation models dedicated to human longevity science.</p> <p>As aging populations reshape global labor markets and consumer demand, longevity has transcended its origins as a niche scientific pursuit to become a major economic pillar. According to recent analysis by <span>UBS</span>, the global longevity market is currently http://www.streetinsider.com/PRNewswire/Insilico+Medicine+and+Human+Longevity+Announce+Collaboration+to+Co-Develop+Industry-First+AI+Foundation+Model+for+Longevity+Science/26547128.html Tue, 26 May 2026 09:41:00 -0400 3696 A.11003533 O.24152401 O15 http://www.streetinsider.com/PRNewswire/Insilico+Medicine+and+Human+Longevity+Announce+Collaboration+to+Co-Develop+Industry-First+AI+Foundation+Model+for+Longevity+Science/26547128.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >Cambridge, Mass.</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, and <span>Human Life Foundation Models, Inc.</span> (HLFM), a newly launched company established by <span value="ACORN:1100353349" idsrc="xmltag.org" >Human Longevity, Inc.</span> today announced a multi-million-dollar AI co-development collaboration to build industry's first large-scale foundation models dedicated to human longevity science.</p> <p>As aging populations reshape global labor markets and consumer demand, longevity has transcended its origins as a niche scientific pursuit to become a major economic pillar. According to recent analysis by <span>UBS</span>, the global longevity market is currently http://www.streetinsider.com/PRNewswire/Insilico+Medicine+and+Human+Longevity+Announce+Collaboration+to+Co-Develop+Industry-First+AI+Foundation+Model+for+Longevity+Science/26547128.html Tue, 26 May 2026 09:41:00 -0400 3696 A.11003533 O.24152401 O15 http://www.streetinsider.com/PRNewswire/Insilico+Medicine+and+Human+Longevity+Announce+Collaboration+to+Co-Develop+Industry-First+AI+Foundation+Model+for+Longevity+Science/26547128.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >Cambridge, Mass.</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, and <span>Human Life Foundation Models, Inc.</span> (HLFM), a newly launched company established by <span value="ACORN:1100353349" idsrc="xmltag.org" >Human Longevity, Inc.</span> today announced a multi-million-dollar AI co-development collaboration to build industry's first large-scale foundation models dedicated to human longevity science.</p> <p>As aging populations reshape global labor markets and consumer demand, longevity has transcended its origins as a niche scientific pursuit to become a major economic pillar. According to recent analysis by <span>UBS</span>, the global longevity market is currently http://www.streetinsider.com/PRNewswire/Insilico+Medicine+and+Human+Longevity+Announce+Collaboration+to+Co-Develop+Industry-First+AI+Foundation+Model+for+Longevity+Science/26547128.html Tue, 26 May 2026 09:41:00 -0400 3696 A.11003533 O.24152401 O15 http://www.streetinsider.com/PRNewswire/Insilico+Medicine+and+Human+Longevity+Announce+Collaboration+to+Co-Develop+Industry-First+AI+Foundation+Model+for+Longevity+Science/26547128.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >Cambridge, Mass.</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, and <span>Human Life Foundation Models, Inc.</span> (HLFM), a newly launched company established by <span value="ACORN:1100353349" idsrc="xmltag.org" >Human Longevity, Inc.</span> today announced a multi-million-dollar AI co-development collaboration to build industry's first large-scale foundation models dedicated to human longevity science.</p> <p>As aging populations reshape global labor markets and consumer demand, longevity has transcended its origins as a niche scientific pursuit to become a major economic pillar. According to recent analysis by <span>UBS</span>, the global longevity market is currently http://www.streetinsider.com/PRNewswire/Insilico+Medicine+and+Human+Longevity+Announce+Collaboration+to+Co-Develop+Industry-First+AI+Foundation+Model+for+Longevity+Science/26547128.html Tue, 26 May 2026 09:41:00 -0400 3696 A.11003533 O.24152401 O15 http://www.streetinsider.com/Press+Releases/Insilico+Medicine+and+Ribo+Enter+Strategic+Collaboration+Agreement%3A+Leveraging+AI+Platform+and+Automated+Lab+for+End-to-End+Empowerment+of+RNA+Interference+and+Oligonucleotide+Therapeutics+Development/26473697.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>May 12, 2026</chron></span> /PRNewswire/ --<b> Insilico Medicine (</b>"<b>Insilico</b>"<b>, 03696.HK), a biotechnology company powered by generative artificial intelligence</b>, today announced that the company has entered a strategic collaboration agreement with Suzhou Ribo Life Science Co., Ltd.  <b>(</b>"<b>Ribo</b>"<b>, 06938.HK), a globally leading clinical-stage company in oligonucleotide therapeutics</b>. Building upon the automation, intelligence and scalability capabilities of Insilico's LifeStar 2 laboratory, the two parties will further deepen the existing experimental service cooperation, combining the end-to-end R&amp;D capabilities of Insilico's proprietary Pharma.AI platform with Ribo's profound expertise in oligonucleotide therapeutics development, aiming for comprehensive efficiency boost in http://www.streetinsider.com/Press+Releases/Insilico+Medicine+and+Ribo+Enter+Strategic+Collaboration+Agreement%3A+Leveraging+AI+Platform+and+Automated+Lab+for+End-to-End+Empowerment+of+RNA+Interference+and+Oligonucleotide+Therapeutics+Development/26473697.html Tue, 12 May 2026 08:30:00 -0400 3696 A.50210275 O.31525930 O15 http://www.streetinsider.com/Press+Releases/Insilico+Medicine+and+Ribo+Enter+Strategic+Collaboration+Agreement%3A+Leveraging+AI+Platform+and+Automated+Lab+for+End-to-End+Empowerment+of+RNA+Interference+and+Oligonucleotide+Therapeutics+Development/26473697.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>May 12, 2026</chron></span> /PRNewswire/ --<b> Insilico Medicine (</b>"<b>Insilico</b>"<b>, 03696.HK), a biotechnology company powered by generative artificial intelligence</b>, today announced that the company has entered a strategic collaboration agreement with Suzhou Ribo Life Science Co., Ltd.  <b>(</b>"<b>Ribo</b>"<b>, 06938.HK), a globally leading clinical-stage company in oligonucleotide therapeutics</b>. Building upon the automation, intelligence and scalability capabilities of Insilico's LifeStar 2 laboratory, the two parties will further deepen the existing experimental service cooperation, combining the end-to-end R&amp;D capabilities of Insilico's proprietary Pharma.AI platform with Ribo's profound expertise in oligonucleotide therapeutics development, aiming for comprehensive efficiency boost in http://www.streetinsider.com/Press+Releases/Insilico+Medicine+and+Ribo+Enter+Strategic+Collaboration+Agreement%3A+Leveraging+AI+Platform+and+Automated+Lab+for+End-to-End+Empowerment+of+RNA+Interference+and+Oligonucleotide+Therapeutics+Development/26473697.html Tue, 12 May 2026 08:30:00 -0400 3696 A.50210275 O.31525930 O15 http://www.streetinsider.com/Press+Releases/Insilico+Medicine+and+Ribo+Enter+Strategic+Collaboration+Agreement%3A+Leveraging+AI+Platform+and+Automated+Lab+for+End-to-End+Empowerment+of+RNA+Interference+and+Oligonucleotide+Therapeutics+Development/26473697.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>May 12, 2026</chron></span> /PRNewswire/ --<b> Insilico Medicine (</b>"<b>Insilico</b>"<b>, 03696.HK), a biotechnology company powered by generative artificial intelligence</b>, today announced that the company has entered a strategic collaboration agreement with Suzhou Ribo Life Science Co., Ltd.  <b>(</b>"<b>Ribo</b>"<b>, 06938.HK), a globally leading clinical-stage company in oligonucleotide therapeutics</b>. Building upon the automation, intelligence and scalability capabilities of Insilico's LifeStar 2 laboratory, the two parties will further deepen the existing experimental service cooperation, combining the end-to-end R&amp;D capabilities of Insilico's proprietary Pharma.AI platform with Ribo's profound expertise in oligonucleotide therapeutics development, aiming for comprehensive efficiency boost in http://www.streetinsider.com/Press+Releases/Insilico+Medicine+and+Ribo+Enter+Strategic+Collaboration+Agreement%3A+Leveraging+AI+Platform+and+Automated+Lab+for+End-to-End+Empowerment+of+RNA+Interference+and+Oligonucleotide+Therapeutics+Development/26473697.html Tue, 12 May 2026 08:30:00 -0400 3696 A.50210275 O.31525930 O15 http://www.streetinsider.com/Press+Releases/Insilico+Medicine+and+Ribo+Enter+Strategic+Collaboration+Agreement%3A+Leveraging+AI+Platform+and+Automated+Lab+for+End-to-End+Empowerment+of+RNA+Interference+and+Oligonucleotide+Therapeutics+Development/26473697.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>May 12, 2026</chron></span> /PRNewswire/ --<b> Insilico Medicine (</b>"<b>Insilico</b>"<b>, 03696.HK), a biotechnology company powered by generative artificial intelligence</b>, today announced that the company has entered a strategic collaboration agreement with Suzhou Ribo Life Science Co., Ltd.  <b>(</b>"<b>Ribo</b>"<b>, 06938.HK), a globally leading clinical-stage company in oligonucleotide therapeutics</b>. Building upon the automation, intelligence and scalability capabilities of Insilico's LifeStar 2 laboratory, the two parties will further deepen the existing experimental service cooperation, combining the end-to-end R&amp;D capabilities of Insilico's proprietary Pharma.AI platform with Ribo's profound expertise in oligonucleotide therapeutics development, aiming for comprehensive efficiency boost in http://www.streetinsider.com/Press+Releases/Insilico+Medicine+and+Ribo+Enter+Strategic+Collaboration+Agreement%3A+Leveraging+AI+Platform+and+Automated+Lab+for+End-to-End+Empowerment+of+RNA+Interference+and+Oligonucleotide+Therapeutics+Development/26473697.html Tue, 12 May 2026 08:30:00 -0400 3696 A.50210275 O.31525930 O15 http://www.streetinsider.com/PRNewswire/Insilico+Medicine+and+Ribo+Enter+Strategic+Collaboration+Agreement%3A+Leveraging+AI+Platform+and+Automated+Lab+for+End-to-End+Empowerment+of+RNA+Interference+and+Oligonucleotide+Therapeutics+Development/26473697.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>May 12, 2026</chron></span> /PRNewswire/ --<b> Insilico Medicine (</b>"<b>Insilico</b>"<b>, 03696.HK), a biotechnology company powered by generative artificial intelligence</b>, today announced that the company has entered a strategic collaboration agreement with Suzhou Ribo Life Science Co., Ltd.  <b>(</b>"<b>Ribo</b>"<b>, 06938.HK), a globally leading clinical-stage company in oligonucleotide therapeutics</b>. Building upon the automation, intelligence and scalability capabilities of Insilico's LifeStar 2 laboratory, the two parties will further deepen the existing experimental service cooperation, combining the end-to-end R&amp;D capabilities of Insilico's proprietary Pharma.AI platform with Ribo's profound expertise in oligonucleotide therapeutics development, aiming for comprehensive efficiency boost in http://www.streetinsider.com/PRNewswire/Insilico+Medicine+and+Ribo+Enter+Strategic+Collaboration+Agreement%3A+Leveraging+AI+Platform+and+Automated+Lab+for+End-to-End+Empowerment+of+RNA+Interference+and+Oligonucleotide+Therapeutics+Development/26473697.html Tue, 12 May 2026 08:30:00 -0400 3696 A.50210275 O.31525930 O15 http://www.streetinsider.com/PRNewswire/Insilico+Medicine+and+Ribo+Enter+Strategic+Collaboration+Agreement%3A+Leveraging+AI+Platform+and+Automated+Lab+for+End-to-End+Empowerment+of+RNA+Interference+and+Oligonucleotide+Therapeutics+Development/26473697.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>May 12, 2026</chron></span> /PRNewswire/ --<b> Insilico Medicine (</b>"<b>Insilico</b>"<b>, 03696.HK), a biotechnology company powered by generative artificial intelligence</b>, today announced that the company has entered a strategic collaboration agreement with Suzhou Ribo Life Science Co., Ltd.  <b>(</b>"<b>Ribo</b>"<b>, 06938.HK), a globally leading clinical-stage company in oligonucleotide therapeutics</b>. Building upon the automation, intelligence and scalability capabilities of Insilico's LifeStar 2 laboratory, the two parties will further deepen the existing experimental service cooperation, combining the end-to-end R&amp;D capabilities of Insilico's proprietary Pharma.AI platform with Ribo's profound expertise in oligonucleotide therapeutics development, aiming for comprehensive efficiency boost in http://www.streetinsider.com/PRNewswire/Insilico+Medicine+and+Ribo+Enter+Strategic+Collaboration+Agreement%3A+Leveraging+AI+Platform+and+Automated+Lab+for+End-to-End+Empowerment+of+RNA+Interference+and+Oligonucleotide+Therapeutics+Development/26473697.html Tue, 12 May 2026 08:30:00 -0400 3696 A.50210275 O.31525930 O15 http://www.streetinsider.com/PRNewswire/Insilico+Medicine+and+Ribo+Enter+Strategic+Collaboration+Agreement%3A+Leveraging+AI+Platform+and+Automated+Lab+for+End-to-End+Empowerment+of+RNA+Interference+and+Oligonucleotide+Therapeutics+Development/26473697.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>May 12, 2026</chron></span> /PRNewswire/ --<b> Insilico Medicine (</b>"<b>Insilico</b>"<b>, 03696.HK), a biotechnology company powered by generative artificial intelligence</b>, today announced that the company has entered a strategic collaboration agreement with Suzhou Ribo Life Science Co., Ltd.  <b>(</b>"<b>Ribo</b>"<b>, 06938.HK), a globally leading clinical-stage company in oligonucleotide therapeutics</b>. Building upon the automation, intelligence and scalability capabilities of Insilico's LifeStar 2 laboratory, the two parties will further deepen the existing experimental service cooperation, combining the end-to-end R&amp;D capabilities of Insilico's proprietary Pharma.AI platform with Ribo's profound expertise in oligonucleotide therapeutics development, aiming for comprehensive efficiency boost in http://www.streetinsider.com/PRNewswire/Insilico+Medicine+and+Ribo+Enter+Strategic+Collaboration+Agreement%3A+Leveraging+AI+Platform+and+Automated+Lab+for+End-to-End+Empowerment+of+RNA+Interference+and+Oligonucleotide+Therapeutics+Development/26473697.html Tue, 12 May 2026 08:30:00 -0400 3696 A.50210275 O.31525930 O15 http://www.streetinsider.com/PRNewswire/Insilico+Medicine+and+Ribo+Enter+Strategic+Collaboration+Agreement%3A+Leveraging+AI+Platform+and+Automated+Lab+for+End-to-End+Empowerment+of+RNA+Interference+and+Oligonucleotide+Therapeutics+Development/26473697.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>May 12, 2026</chron></span> /PRNewswire/ --<b> Insilico Medicine (</b>"<b>Insilico</b>"<b>, 03696.HK), a biotechnology company powered by generative artificial intelligence</b>, today announced that the company has entered a strategic collaboration agreement with Suzhou Ribo Life Science Co., Ltd.  <b>(</b>"<b>Ribo</b>"<b>, 06938.HK), a globally leading clinical-stage company in oligonucleotide therapeutics</b>. Building upon the automation, intelligence and scalability capabilities of Insilico's LifeStar 2 laboratory, the two parties will further deepen the existing experimental service cooperation, combining the end-to-end R&amp;D capabilities of Insilico's proprietary Pharma.AI platform with Ribo's profound expertise in oligonucleotide therapeutics development, aiming for comprehensive efficiency boost in http://www.streetinsider.com/PRNewswire/Insilico+Medicine+and+Ribo+Enter+Strategic+Collaboration+Agreement%3A+Leveraging+AI+Platform+and+Automated+Lab+for+End-to-End+Empowerment+of+RNA+Interference+and+Oligonucleotide+Therapeutics+Development/26473697.html Tue, 12 May 2026 08:30:00 -0400 3696 A.50210275 O.31525930 O15 http://www.streetinsider.com/Press+Releases/Insilico%27s+Rentosertib+Inhalation+Solution+Receives+IND+Clearance+for+the+World%27s+First+AI-Driven+Candidate+to+Enter+Direct-to-Lung+Clinical+Study/26386015.html <div class="xn-content"> <ul type="disc"><li>Following positive Phase IIa results for oral Rentosertib in GENESIS-IPF with good tolerability, a favorable PK profile, and dose-dependent efficacy improvements, the inhalation solution has received IND clearance from the CDE.</li><li>The inhalation solution is designed for targeted lung delivery to achieve rapid onset and high local bioavailability at lower doses, while reducing systemic exposure and related side effects.</li><li>Rentosertib inhalation solution is the 13th program from Insilico's AI-driven pipeline to receive IND clearance, further demonstrating how <a target="_blank" href="http://pharma.ai" target="_blank" rel="nofollow">Pharma.AI</a> could reproducibly drive the discovery and development of novel molecules from preclinical development to clinical validation.</li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" http://www.streetinsider.com/Press+Releases/Insilico%27s+Rentosertib+Inhalation+Solution+Receives+IND+Clearance+for+the+World%27s+First+AI-Driven+Candidate+to+Enter+Direct-to-Lung+Clinical+Study/26386015.html Tue, 28 Apr 2026 21:00:00 -0400 3696 A.38554088 O.42313267 O15 http://www.streetinsider.com/Press+Releases/Insilico%27s+Rentosertib+Inhalation+Solution+Receives+IND+Clearance+for+the+World%27s+First+AI-Driven+Candidate+to+Enter+Direct-to-Lung+Clinical+Study/26386015.html <div class="xn-content"> <ul type="disc"><li>Following positive Phase IIa results for oral Rentosertib in GENESIS-IPF with good tolerability, a favorable PK profile, and dose-dependent efficacy improvements, the inhalation solution has received IND clearance from the CDE.</li><li>The inhalation solution is designed for targeted lung delivery to achieve rapid onset and high local bioavailability at lower doses, while reducing systemic exposure and related side effects.</li><li>Rentosertib inhalation solution is the 13th program from Insilico's AI-driven pipeline to receive IND clearance, further demonstrating how <a target="_blank" href="http://pharma.ai" target="_blank" rel="nofollow">Pharma.AI</a> could reproducibly drive the discovery and development of novel molecules from preclinical development to clinical validation.</li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" http://www.streetinsider.com/Press+Releases/Insilico%27s+Rentosertib+Inhalation+Solution+Receives+IND+Clearance+for+the+World%27s+First+AI-Driven+Candidate+to+Enter+Direct-to-Lung+Clinical+Study/26386015.html Tue, 28 Apr 2026 21:00:00 -0400 3696 A.38554088 O.42313267 O15 http://www.streetinsider.com/Press+Releases/Insilico%27s+Rentosertib+Inhalation+Solution+Receives+IND+Clearance+for+the+World%27s+First+AI-Driven+Candidate+to+Enter+Direct-to-Lung+Clinical+Study/26386015.html <div class="xn-content"> <ul type="disc"><li>Following positive Phase IIa results for oral Rentosertib in GENESIS-IPF with good tolerability, a favorable PK profile, and dose-dependent efficacy improvements, the inhalation solution has received IND clearance from the CDE.</li><li>The inhalation solution is designed for targeted lung delivery to achieve rapid onset and high local bioavailability at lower doses, while reducing systemic exposure and related side effects.</li><li>Rentosertib inhalation solution is the 13th program from Insilico's AI-driven pipeline to receive IND clearance, further demonstrating how <a target="_blank" href="http://pharma.ai" target="_blank" rel="nofollow">Pharma.AI</a> could reproducibly drive the discovery and development of novel molecules from preclinical development to clinical validation.</li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" http://www.streetinsider.com/Press+Releases/Insilico%27s+Rentosertib+Inhalation+Solution+Receives+IND+Clearance+for+the+World%27s+First+AI-Driven+Candidate+to+Enter+Direct-to-Lung+Clinical+Study/26386015.html Tue, 28 Apr 2026 21:00:00 -0400 3696 A.38554088 O.42313267 O15 http://www.streetinsider.com/Press+Releases/Insilico%27s+Rentosertib+Inhalation+Solution+Receives+IND+Clearance+for+the+World%27s+First+AI-Driven+Candidate+to+Enter+Direct-to-Lung+Clinical+Study/26386015.html <div class="xn-content"> <ul type="disc"><li>Following positive Phase IIa results for oral Rentosertib in GENESIS-IPF with good tolerability, a favorable PK profile, and dose-dependent efficacy improvements, the inhalation solution has received IND clearance from the CDE.</li><li>The inhalation solution is designed for targeted lung delivery to achieve rapid onset and high local bioavailability at lower doses, while reducing systemic exposure and related side effects.</li><li>Rentosertib inhalation solution is the 13th program from Insilico's AI-driven pipeline to receive IND clearance, further demonstrating how <a target="_blank" href="http://pharma.ai" target="_blank" rel="nofollow">Pharma.AI</a> could reproducibly drive the discovery and development of novel molecules from preclinical development to clinical validation.</li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" http://www.streetinsider.com/Press+Releases/Insilico%27s+Rentosertib+Inhalation+Solution+Receives+IND+Clearance+for+the+World%27s+First+AI-Driven+Candidate+to+Enter+Direct-to-Lung+Clinical+Study/26386015.html Tue, 28 Apr 2026 21:00:00 -0400 3696 A.38554088 O.42313267 O15 http://www.streetinsider.com/PRNewswire/Insilico%27s+Rentosertib+Inhalation+Solution+Receives+IND+Clearance+for+the+World%27s+First+AI-Driven+Candidate+to+Enter+Direct-to-Lung+Clinical+Study/26386015.html <div class="xn-content"> <ul type="disc"><li>Following positive Phase IIa results for oral Rentosertib in GENESIS-IPF with good tolerability, a favorable PK profile, and dose-dependent efficacy improvements, the inhalation solution has received IND clearance from the CDE.</li><li>The inhalation solution is designed for targeted lung delivery to achieve rapid onset and high local bioavailability at lower doses, while reducing systemic exposure and related side effects.</li><li>Rentosertib inhalation solution is the 13th program from Insilico's AI-driven pipeline to receive IND clearance, further demonstrating how <a target="_blank" href="http://pharma.ai" target="_blank" rel="nofollow">Pharma.AI</a> could reproducibly drive the discovery and development of novel molecules from preclinical development to clinical validation.</li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" http://www.streetinsider.com/PRNewswire/Insilico%27s+Rentosertib+Inhalation+Solution+Receives+IND+Clearance+for+the+World%27s+First+AI-Driven+Candidate+to+Enter+Direct-to-Lung+Clinical+Study/26386015.html Tue, 28 Apr 2026 21:00:00 -0400 3696 A.38554088 O.42313267 O15 http://www.streetinsider.com/PRNewswire/Insilico%27s+Rentosertib+Inhalation+Solution+Receives+IND+Clearance+for+the+World%27s+First+AI-Driven+Candidate+to+Enter+Direct-to-Lung+Clinical+Study/26386015.html <div class="xn-content"> <ul type="disc"><li>Following positive Phase IIa results for oral Rentosertib in GENESIS-IPF with good tolerability, a favorable PK profile, and dose-dependent efficacy improvements, the inhalation solution has received IND clearance from the CDE.</li><li>The inhalation solution is designed for targeted lung delivery to achieve rapid onset and high local bioavailability at lower doses, while reducing systemic exposure and related side effects.</li><li>Rentosertib inhalation solution is the 13th program from Insilico's AI-driven pipeline to receive IND clearance, further demonstrating how <a target="_blank" href="http://pharma.ai" target="_blank" rel="nofollow">Pharma.AI</a> could reproducibly drive the discovery and development of novel molecules from preclinical development to clinical validation.</li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" http://www.streetinsider.com/PRNewswire/Insilico%27s+Rentosertib+Inhalation+Solution+Receives+IND+Clearance+for+the+World%27s+First+AI-Driven+Candidate+to+Enter+Direct-to-Lung+Clinical+Study/26386015.html Tue, 28 Apr 2026 21:00:00 -0400 3696 A.38554088 O.42313267 O15 http://www.streetinsider.com/PRNewswire/Insilico%27s+Rentosertib+Inhalation+Solution+Receives+IND+Clearance+for+the+World%27s+First+AI-Driven+Candidate+to+Enter+Direct-to-Lung+Clinical+Study/26386015.html <div class="xn-content"> <ul type="disc"><li>Following positive Phase IIa results for oral Rentosertib in GENESIS-IPF with good tolerability, a favorable PK profile, and dose-dependent efficacy improvements, the inhalation solution has received IND clearance from the CDE.</li><li>The inhalation solution is designed for targeted lung delivery to achieve rapid onset and high local bioavailability at lower doses, while reducing systemic exposure and related side effects.</li><li>Rentosertib inhalation solution is the 13th program from Insilico's AI-driven pipeline to receive IND clearance, further demonstrating how <a target="_blank" href="http://pharma.ai" target="_blank" rel="nofollow">Pharma.AI</a> could reproducibly drive the discovery and development of novel molecules from preclinical development to clinical validation.</li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" http://www.streetinsider.com/PRNewswire/Insilico%27s+Rentosertib+Inhalation+Solution+Receives+IND+Clearance+for+the+World%27s+First+AI-Driven+Candidate+to+Enter+Direct-to-Lung+Clinical+Study/26386015.html Tue, 28 Apr 2026 21:00:00 -0400 3696 A.38554088 O.42313267 O15 http://www.streetinsider.com/PRNewswire/Insilico%27s+Rentosertib+Inhalation+Solution+Receives+IND+Clearance+for+the+World%27s+First+AI-Driven+Candidate+to+Enter+Direct-to-Lung+Clinical+Study/26386015.html <div class="xn-content"> <ul type="disc"><li>Following positive Phase IIa results for oral Rentosertib in GENESIS-IPF with good tolerability, a favorable PK profile, and dose-dependent efficacy improvements, the inhalation solution has received IND clearance from the CDE.</li><li>The inhalation solution is designed for targeted lung delivery to achieve rapid onset and high local bioavailability at lower doses, while reducing systemic exposure and related side effects.</li><li>Rentosertib inhalation solution is the 13th program from Insilico's AI-driven pipeline to receive IND clearance, further demonstrating how <a target="_blank" href="http://pharma.ai" target="_blank" rel="nofollow">Pharma.AI</a> could reproducibly drive the discovery and development of novel molecules from preclinical development to clinical validation.</li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" http://www.streetinsider.com/PRNewswire/Insilico%27s+Rentosertib+Inhalation+Solution+Receives+IND+Clearance+for+the+World%27s+First+AI-Driven+Candidate+to+Enter+Direct-to-Lung+Clinical+Study/26386015.html Tue, 28 Apr 2026 21:00:00 -0400 3696 A.38554088 O.42313267 O15 http://www.streetinsider.com/Press+Releases/Generative+AI+Leap%3A+Insilico+Medicine+Nominates+First+Preclinical+Candidate+in+the+UAE/26362879.html <div class="xn-content"> <ul type="disc"><li>For its 30th PCC anniversary, Insilico Medicine nominated ISM0387, the first <location value="LC/ae" idsrc="xmltag.org" >UAE</location>-based preclinical candidate, jointly announced with the Emirates Drug Establishment (EDE), with the support of local partners including Abu Dhabi Investment Office (ADIO), the <span>Department of Health Abu Dhabi</span> (DoH) and other prominent ecosystem <span id="spanHghlt20e8">players.</span></li><li>ISM0387 is an MTA-cooperative PRMT5 inhibitor with AI-powered novel structure, showing improved <i>in vitro</i> activity and selectivity, enhanced brain penetrant properties, and robust, dose-dependent efficacy in disease models.</li><li>The discovery process of ISM0387 is local, and it signals that the UAE has evolved into a technology-driven powerhouse with a knowledge-based "Falcon Economy."</li><li>Based on http://www.streetinsider.com/Press+Releases/Generative+AI+Leap%3A+Insilico+Medicine+Nominates+First+Preclinical+Candidate+in+the+UAE/26362879.html Fri, 24 Apr 2026 09:00:00 -0400 3696 A.26803806 A.50204806 A.50210275 O.00178031 O.12398575 O.31525930 O15